Loading…
Zevra Therapeutics, Inc. is projected to rise to $20.10 by 2027, a +51% move from its current price of $13.35. ZVRA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $12.96 | $13.36 | $13.78 | +0.09% |
| Jul 14 | $12.81 | $13.37 | $13.96 | +0.18% |
| Jul 15 | $12.70 | $13.39 | $14.11 | +0.27% |
| Jul 16 | $12.61 | $13.40 | $14.24 | +0.37% |
| Jul 17 | $12.53 | $13.41 | $14.36 | +0.46% |
| Jul 18 | $12.46 | $13.42 | $14.47 | +0.55% |
| Jul 19 | $12.39 | $13.44 | $14.57 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.39 | $13.44 | $14.57 | +0.64% |
| Week 2 | $12.06 | $13.52 | $15.16 | +1.29% |
| Week 3 | $11.83 | $13.61 | $15.65 | +1.94% |
| Week 4 | $11.65 | $13.70 | $16.10 | +2.60% |
| Week 5 | $11.51 | $13.78 | $16.51 | +3.26% |
| Week 6 | $11.38 | $13.87 | $16.91 | +3.92% |
| Week 7 | $11.28 | $13.96 | $17.29 | +4.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zevra Therapeutics, Inc. is a commercial-stage healthcare company focused on addressing unmet needs for the treatment of rare diseases in the United States. It develops its products through Ligand Activated Technology platform.
Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
In addition, Zevra offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of Niemann-Pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Zevra Therapeutics, Inc. (ZVRA) trades at $14.01 per share and has a market capitalization of $828.2M. It is ranked 2571.
The 2026 forecast shows a min of $8.31, an avg of $14.01, and a max of $19.65; ROI 0% and sentiment NEUTRAL.
From 2027 onward, the forecast is bullish with rising averages through 2030 ($38.41), 2040 ($139.06), and 2050 ($314.42). The maximum forecast prices reach as high as $615.74 by 2050.
A major floor 34.4% below — a decisive break under it would weaken the trend.
The nearest floor, 20.5% below — buyers have tended to step in here.
The nearest ceiling, 10.5% above — a clean break opens room to run.
A major ceiling 27.7% above — clearing it would confirm fresh momentum.
Key ZVRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZVRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.09 | Sell | $13.90 | Sell |
| MA 10 | $14.01 | Sell | $13.83 | Sell |
| MA 20 | $13.42 | Sell | $13.40 | Sell |
| MA 50 | $11.96 | Buy | $12.27 | Buy |
| MA 100 | $10.75 | Buy | $11.26 | Buy |
| MA 200 | $9.99 | Buy | $10.37 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.70 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -7.80 | Neutral |
| Williams %R (14) | -66.67 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 2.69 | Buy |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 33.33 | Neutral |
| TRIX (15) | 0.83 | Buy |
| Awesome (5,34) | 1.52 | Buy |
| Ultimate (7,14,28) | 42.69 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 14.14 | Sell |
| ADX (14) | 24.63 | Buy |
| ATR (14) | 0.38 | Info |
The 30-day technical picture shows bullish sentiment, with RSI14 at 70. The market displays key levels: SMA50 at $11.35 and SMA200 at $9.73, with a nearby resistance at $14.01 and a support at $10.03. The current price sits at $14.01, within a 30-day range of $11.37 to $17.26.
This setup suggests a positive near-term bias, supported by a bullish backdrop while remaining within a defined support and resistance framework. Investors may watch the $14.01 resistance for potential upside and the $10.03 support for downside protection over the next month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.31 | $13.35 | $18.60 | 0% | Neutral | |
| $15.82 | $20.10 | $27.11 | +51% | Bullish | |
| $20.15 | $26.42 | $37.11 | +98% | Bullish | |
| $25.05 | $33.71 | $48.88 | +153% | Bullish | |
| $26.78 | $36.88 | $54.93 | +176% | Bullish | |
| $27.70 | $38.97 | $59.39 | +192% | Bullish | |
| $33.74 | $48.43 | $75.36 | +263% | Bullish | |
| $36.59 | $53.50 | $84.83 | +301% | Bullish | |
| $44.33 | $65.99 | $106.45 | +394% | Bullish | |
| $56.03 | $84.84 | $139.05 | +535% | Bullish | |
| $78.54 | $128.55 | $225.23 | +863% | Bullish | |
| $162.54 | $304.87 | $588.38 | +21.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.31 | $13.35 | $16.24 | +0.00% |
| August 2026 | $12.11 | $14.34 | $17.47 | +7.42% |
| September 2026 | $12.16 | $14.51 | $17.90 | +1.20% |
| October 2026 | $11.74 | $14.11 | $17.58 | -2.78% |
| November 2026 | $11.81 | $14.27 | $17.94 | +1.16% |
| December 2026 | $12.08 | $14.68 | $18.60 | +2.86% |
Click any year to see its month-by-month ZVRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zevra Therapeutics, Inc.'s 2026 outlook centres on $13.35, within a $8.31 to $18.60 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ZVRA could reach as high as $27.11, with a base case around $20.10 and support toward $15.82 — roughly +51% from $13.35. Buyers look set to stay in control over this stretch.
Expect ZVRA to range from $20.15 to $37.11 through 2028. The $26.42 average target implies a +98% move from current prices. That is up +31% on the projected 2027 average. Momentum favours further upside here.
The ZVRA price prediction for 2029 points to an average of $33.71 (low $25.05, high $48.88) — a potential gain of +153% on today's $13.35. Buyers look set to stay in control over this stretch.
In 2030, ZVRA is projected to trade between $26.78 and $54.93, averaging $36.88 — a potential gain of +176% from today's $13.35. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Zevra Therapeutics, Inc.'s 2031 outlook centres on $38.97, within a $27.70 to $59.39 range. That is up +6% on the projected 2030 average. That marks a +192% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ZVRA could reach as high as $75.36, with a base case around $48.43 and support toward $33.74 — roughly +263% from $13.35. Momentum favours further upside here.
Expect ZVRA to range from $36.59 to $84.83 through 2033. The $53.50 average target implies a +301% move from current prices. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ZVRA price prediction for 2034 points to an average of $65.99 (low $44.33, high $106.45) — a potential gain of +394% on today's $13.35. Momentum favours further upside here.
In 2035, ZVRA is projected to trade between $56.03 and $139.05, averaging $84.84 — a potential gain of +535% from today's $13.35. That is up +29% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Zevra Therapeutics, Inc.'s 2040 outlook centres on $128.55, within a $78.54 to $225.23 range. That is up +52% on the projected 2035 average. That marks a +863% change versus current levels. Momentum favours further upside here.
By 2050, ZVRA could reach as high as $588.38, with a base case around $304.87 and support toward $162.54 — roughly +21.8x from $13.35. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZVRA today (≈ 74.906367 ZVRA) could be worth
$22,836.66
+$21,836.66 (+2184%) by 2050 · US Dollar
Based on the average projected ZVRA price of $304.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZVRAwould be worth at today's price.
$1,000 invested in ZVRA on Jul 10, 2025 (≈ 83.194672 ZVRA) would be worth
$1,110.65
+$110.65 (+11.1%) today · 1.11× · US Dollar
Based on a ZVRA entry price of $12.02 vs. today's $13.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.98 | $954.94 | -4.5% |
| 1 month ago | $13.5 | $988.89 | -1.1% |
| 3 months ago | $9.47 | $1,409.71 | +41.0% |
| 6 months ago | $8.38 | $1,593.08 | +59.3% |
| 1 year ago | $12.02 | $1,110.65 | +11.1% |
| All time (5.0y) ago | $12.16 | $1,097.86 | +9.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZVRA forecast.
Our base-case forecast reaches $27.00 around 2029.
Implied market cap at $27.00: $1.6B
The multi-year forecast paints a strong upside trajectory with a series of rising averages and substantial ROI potential. In 2030 the average price is forecast at $38.41 with a min of $27.67, a max of $57.71 and an ROI of 174.2%, supported by a bullish sentiment.
In 2040 the average price is forecast at $139.06 with a min of $83.61, a max of $246.72 and an ROI of 892.6%, continuing the bullish outlook.
By 2050 the average price is forecast at $314.42 with a min of $163.72, a max of $615.74 and an ROI of 2144.2%, with sentiment remaining BULLISH. These figures illustrate meaningful long-term upside potential while highlighting that these are estimates, not guarantees.
Overall, the long-range view supports higher price targets across the horizon, but investors should consider the inherent uncertainty and the fact that forecasts are not guarantees of future results.
Tap a question to reveal the answer.
2030 avg $38.41; min $27.67; max $57.71; ROI 174.2%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising average prices and positive ROI figures (e.g., 2027 ROI 53.3%, 2032 ROI 262.4%, 2040 ROI 892.6%, 2050 ROI 2144.2%), but these are estimates, not guarantees.
Yes—the forecast includes high price targets well above $100, with 2035 max $148.76, 2040 max $246.72, and 2050 max $615.74.
Current price $14.01; market cap $828.2M.
RSI14 is 70. The 30-day range is $11.37–$17.26; SMA50 is $11.35; SMA200 is $9.73; support is $10.03 and resistance is $14.01.
Zevra Therapeutics, Inc. Community Discussion
0Share your Zevra Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.